Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Kamil Kuś et al.|Cancer Research|2025Cited by 1
Abstract 755: Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancerTomasz Rzymski, Krzysztof Brzózka, Małgorzata Szajewska-Skuta et al.|Cancer Research|2014Cited by 0